US Patent

US7919483 — Method for the treatment of acne

Method of Use · Assigned to Medicis Pharmaceutical Corp · Expires 2027-03-07 · 1y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for treating acne using tetracyclines, specifically employing a lower sustained dose and optional once-a-day dosing regimen.

USPTO Abstract

A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.

Drugs covered by this patent

minocycline-hydrochloride (MINOCYCLINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1078`	—	minocycline-hydrochloride
`U-124`	—	minocycline-hydrochloride
`U-124`	—	minocycline-hydrochloride
`U-1078`	—	minocycline-hydrochloride
`U-124`	—	minocycline-hydrochloride
`U-1078`	—	minocycline-hydrochloride
`U-1078`	—	minocycline-hydrochloride
`U-1078`	—	minocycline-hydrochloride
`U-1078`	—	minocycline-hydrochloride
`U-1078`	—	minocycline-hydrochloride
`U-1078`	—	minocycline-hydrochloride

Patent Metadata

Patent number: US7919483
Jurisdiction: US
Classification: Method of Use
Expires: 2027-03-07
Drug substance claim: No
Drug product claim: No
Assignee: Medicis Pharmaceutical Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.